Clinical Impact of Mismatch Repair Gene Mutation-Based Alert on Immunotherapy Decision Making Across Patients With Cancer
{{output}}
Purpose: Despite approval of pembrolizumab and dostarlimab for tumors that are deficient in mismatch repair (MMR) proteins, many patients do not undergo mismatch repair deficiency (dMMR) testing by immunohistochemistry (IHC). We ... ...
